Cyclerion Therapeutics

Company snapshot

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic dise

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 17 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cyclerion Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Cyclerion Therapeutics.

1. Jun 5, 2026 Clinical update

   Matching Placebo — Phase 2

2. May 23, 2026 Clinical update

   IW-1701 — Phase 2

3. May 23, 2026 Clinical update

   IW-1973 — Phase 2

4. May 23, 2026 Clinical update

   Olinciguat — Phase 2

5. May 23, 2026 Clinical update

   IW-1701 — Phase 1

View all clinical trial activity →

• What is Cyclerion Therapeutics?

  Cyclo Therapeutics is a pharma organization headquartered in Gainesville, USA. It trades on NYSE under ticker CYCN. Primary therapeutic focus areas include Diabetes Mellitus, Type 2, Sickle Cell Disease, Achalasia. NovaPharmaNews links 9 clinical program(s), 0 drug profile(s), an

• Is Cyclerion Therapeutics publicly traded?

  Yes. Cyclerion Therapeutics is listed with ticker CYCN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Cyclerion Therapeutics develop or market?

  We link 2 drug profile(s) where Cyclerion Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cyclerion-therapeutics#company-drugs.

• What are the latest developments for Cyclerion Therapeutics?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Cyclerion Therapeutics focus on?

  Cyclerion Therapeutics focuses on Diabetes Mellitus, Type 2, Sickle Cell Disease, Achalasia based on our analysis of their pipeline programs and drug development activities.